• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Boston Scientific enrolls 1st patient in new biliary duct stenting trial

Boston Scientific enrolls 1st patient in new biliary duct stenting trial

December 5, 2012 By MassDevice staff

Boston Scientific logo

Medical device company Boston Scientific (NYSE:BSX) enrolled its 1st patient in a new study evaluating its WallFlex Biliary RX fully covered self-expanding stents, part of the WallFlex suite of stents which the company says "is the most frequently implanted biliary metal stent worldwide."

The new study will compare the WallFlex Biliary RX to plastic stents in treatment of benign bile duct strictures that are caused by chronic pancreatitis, hoping to demonstrate that the metal WallFlex stent can resolve strictures in fewer procedures, according to a press release.

"Multiple plastic stenting remains an established treatment choice for biliary strictures caused by chronic pancreatitis," study investigator Professor Puspok of the Medical University of Vienna, who has worked on other WallFlex studies as well, said in prepared remarks. "However, this form of treatment requires multiple stent exchanges and the long-term success rate is low. Treatment with removable fully covered SEMS could overcome these limitations."

The WallFlex Biliary RX stents are designed to enable removal of the devices for up to 1 year following implant. In a previous single-arm study of the device researchers reported that they were able to safely remove the stents any time within that 1 year and that short-term treatment findings were stronger for WallFlex stents than had been reported in studies of plastic stents.

The previous WallFlex study, which involved 187 patients and launched in January 2010, is still gathered data for a 5-year follow-up, according to a press release.

The new study will involve 164 patients at sites in Australia, Austria, Belgium, Canada, France, Germany, Hong Kong, India, Italy and the Netherlands.

Filed Under: News Well, Research & Development, Stents Tagged With: Boston Scientific, Clinical Trials

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy